This service provides comprehensive clinical pathology and histopathology analysis to support the non-clinical development of healthcare products, including advanced therapies and chemical-based innovations. It covers histological processing and detailed histopathological evaluation, as well as clinical pathology assessments such as biochemistry, hematology, coagulation, and urinalysis. In addition, the service includes tailored advisory support to define an appropriate development roadmap aligned with the product profile and regulatory requirements. The service is designed for EIC beneficiaries, including public research organisations (universities and research institutes) and private sector entities (biotechnology and pharmaceutical companies) developing health-related products such as ATMPs or chemicals. Its primary objective is to evaluate treatment-related effects by analysing microscopic tissue changes and identifying alterations in biological fluids that may indicate systemic toxicity. The duration of the service depends on the number of samples and scope of analysis, typically ranging from a few weeks to several months. The engagement begins with a protocol development phase, during which the study design is defined in close collaboration with the beneficiary. This is followed by study execution, data analysis, and the preparation of a comprehensive final report. For GLP studies, all phases, including protocolisation, execution, analysis, and reporting, are conducted under strict quality control and audited in compliance with GLP requirements. All activities are performed under ISO 9001:2015-certified quality management systems, with GLP compliance applied where required. The service is delivered by in-house scientific teams, supported by internal auditors and regulatory experts to ensure high-quality outputs and adherence to international standards. As a result, beneficiaries receive a detailed and reliable final study report suitable for internal decision-making and/or regulatory use, enabling informed progression of their product development pipeline.
Services are offered on a fee-for-service basis. Quotes depend on study type, number and type of samples. A tailored proposal is prepared after technical discussion. Indicative hourly rates range from €100 to €265, excluding consumables, sample-related materials and any specific external services or equipment requirements.
Final timelines depend on sample number and type, analytical complexity, histopathology and immunohistochemical workload.
Access to Infrastructure & R&D Support
Are you in doubt if this is the right service for you, or do you want to get more information about the service? Get in touch with the EIC Partner providing this service through this query form!
Is this the service you are looking for? If so, you can apply to the service through EIC ACCESS+! Eligible applicants can also get co-funding through the EIC ACCESS+ initiative. Find out more on the project webiste.
Receive up to €60,000 in grants, covering up to 50% of the costs, to access specialised services from the EIC Service Catalogue. Learn more on the EIC ACCESS+ website.